{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:20:50Z","timestamp":1790882450316,"version":"4.1.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T00:00:00Z","timestamp":1456444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00277-016-2621-2","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T01:59:02Z","timestamp":1456451942000},"page":"707-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)"],"prefix":"10.1007","volume":"95","author":[{"given":"Iris","family":"Appelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefani","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Heinrich","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bisping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petro E.","family":"Petrides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Matzdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,26]]},"reference":[{"key":"2621_CR1","unstructured":"Swerdlow SH, International Agency for Research on C, World Health O (2008) WHO classification of tumours of haematopoietic and lymphoid tissues: International Agency for Research on Cancer"},{"issue":"4","key":"2621_CR2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6(4):372\u2013375","journal-title":"Blood"},{"issue":"2","key":"2621_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MOH.0b013e328343998e","volume":"18","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab O (2011) Genetics of the myeloproliferative neoplasms. Curr Opin Hematol 18(2):117\u2013123","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"2621_CR4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","volume":"25","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab O, Pardanani A, Patel J et al (2011) Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25(7):1200\u20131202","journal-title":"Leukemia"},{"issue":"6","key":"2621_CR5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","volume":"111","author":"SL Etheridge","year":"2014","unstructured":"Etheridge SL, Roh ME, Cosgrove ME et al (2014) JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. Proc Natl Acad Sci U S A 111(6):2295\u20132300","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"2621_CR6","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390","journal-title":"N Engl J Med"},{"issue":"22","key":"2621_CR7","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","volume":"123","author":"R Rampal","year":"2014","unstructured":"Rampal R, Al-Shahrour F, Abdel-Wahab O et al (2014) Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123(22):e123\u2013133","journal-title":"Blood"},{"issue":"2","key":"2621_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.beha.2014.07.001","volume":"27","author":"R Rampal","year":"2014","unstructured":"Rampal R, Levine RL (2014) A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. Best Pract Res Clin Haematol 27(2):83\u201393","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"2621_CR9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/leu.2008.229","volume":"22","author":"O Kilpivaara","year":"2008","unstructured":"Kilpivaara O, Levine RL (2008) JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 22(10):1813\u20131817","journal-title":"Leukemia"},{"issue":"5","key":"2621_CR10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12185-015-1871-4","volume":"102","author":"EM Kander","year":"2015","unstructured":"Kander EM, Raza S, Zhou Z et al (2015) Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol 102(5):587\u2013593","journal-title":"Int J Hematol"},{"issue":"1","key":"2621_CR11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33\u201345","journal-title":"N Engl J Med"},{"issue":"5","key":"2621_CR12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","volume":"23","author":"U Budde","year":"1997","unstructured":"Budde U, van Genderen PJ (1997) Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 23(5):425\u2013431","journal-title":"Semin Thromb Hemost"},{"issue":"7","key":"2621_CR13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ajh.21730","volume":"85","author":"A Tefferi","year":"2010","unstructured":"Tefferi A, Smock KJ, Divgi AB (2010) Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count. Am J Hematol 85(7):545","journal-title":"Am J Hematol"},{"issue":"6","key":"2621_CR14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood.V68.6.1213.1213","volume":"68","author":"U Budde","year":"1986","unstructured":"Budde U, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS (1986) Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 68(6):1213\u20131217","journal-title":"Blood"},{"issue":"1","key":"2621_CR15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.1986.tb07497.x","volume":"63","author":"F Fabris","year":"1986","unstructured":"Fabris F, Casonato A, del Ben GM, De Marco L, Girolami A (1986) Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 63(1):75\u201383","journal-title":"Br J Haematol"},{"issue":"2","key":"2621_CR16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajh.2830260204","volume":"26","author":"H Mohri","year":"1987","unstructured":"Mohri H (1987) Acquired von Willebrand disease in patients with polycythemia rubra vera. Am J Hematol 26(2):135\u2013146","journal-title":"Am J Hematol"},{"issue":"2","key":"2621_CR17","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2007-07-102665","volume":"111","author":"M Ruggeri","year":"2008","unstructured":"Ruggeri M, Rodeghiero F, Tosetto A et al (2008) Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111(2):666\u2013671","journal-title":"Blood"},{"issue":"2","key":"2621_CR18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-2002-27824","volume":"28","author":"U Budde","year":"2002","unstructured":"Budde U, Bergmann F, Michiels JJ (2002) Acquired von Willebrand syndrome: experience from 2\u00a0years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 28(2):227\u2013238","journal-title":"Semin Thromb Hemost"},{"key":"2621_CR19","doi-asserted-by":"crossref","unstructured":"Tiede A, Klamroth R, Scharf RE, et al (2014) Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study. Blood","DOI":"10.1182\/blood-2014-07-587089"},{"issue":"25","key":"2621_CR20","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","volume":"117","author":"A Tiede","year":"2011","unstructured":"Tiede A, Rand JH, Budde U, Ganser A, Federici AB (2011) How I treat the acquired von Willebrand syndrome. Blood 117(25):6777\u20136785","journal-title":"Blood"},{"issue":"4","key":"2621_CR21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1538-7836.2008.02909.x","volume":"6","author":"A Tiede","year":"2008","unstructured":"Tiede A, Priesack J, Werwitzke S et al (2008) Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 6(4):569\u2013576","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2621_CR22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ajh.23135","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A (2012) Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(3):285\u2013293","journal-title":"Am J Hematol"},{"issue":"22","key":"2621_CR23","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/archinte.165.22.2651","volume":"165","author":"CS Chim","year":"2005","unstructured":"Chim CS, Kwong YL, Lie AK et al (2005) Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 165(22):2651\u20132658","journal-title":"Arch Intern Med"},{"issue":"4 Pt 2","key":"2621_CR24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-2006-942754","volume":"32","author":"JJ Michiels","year":"2006","unstructured":"Michiels JJ, De Raeve H, Berneman Z et al (2006) The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 32(4 Pt 2):307\u2013340","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2621_CR25","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-08-270033","volume":"117","author":"PA Beer","year":"2011","unstructured":"Beer PA, Erber WN, Campbell PJ, Green AR (2011) How I treat essential thrombocythemia. Blood 117(5):1472\u20131482","journal-title":"Blood"},{"key":"2621_CR26","unstructured":"Petro E. Petrides GMB, Heinz Gisslinger, Martin Grie\u00dfhammer, Eva Lengfelder (2014) Essentielle (oder primaere) Thrombozythaemie. DGHO Leitlinien Onkopedia"},{"issue":"2","key":"2621_CR27","first-page":"345","volume":"84","author":"AB Federici","year":"2000","unstructured":"Federici AB, Rand JH, Bucciarelli P et al (2000) Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 84(2):345\u2013349","journal-title":"Thromb Haemost"},{"issue":"4","key":"2621_CR28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1160\/TH10-11-0697","volume":"105","author":"G Castaman","year":"2011","unstructured":"Castaman G, Tosetto A, Federici AB, Rodeghiero F (2011) Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost 105(4):647\u2013654","journal-title":"Thromb Haemost"},{"issue":"4","key":"2621_CR29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","volume":"167","author":"MA Laffan","year":"2014","unstructured":"Laffan MA, Lester W, O\u2019Donnell JS et al (2014) The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British committee for standards in haematology. Br J Haematol 167(4):453\u2013465","journal-title":"Br J Haematol"},{"issue":"1","key":"2621_CR30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2516.2011.02573.x","volume":"18","author":"DE Trigg","year":"2012","unstructured":"Trigg DE, Stergiotou I, Peitsidis P, Kadir RA (2012) A systematic review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia 18(1):25\u201333","journal-title":"Haemophilia"},{"issue":"3","key":"2621_CR31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2516.2004.00886.x","volume":"10","author":"KJ Pasi","year":"2004","unstructured":"Pasi KJ, Collins PW, Keeling DM et al (2004) Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors\u2019 Organization. Haemophilia 10(3):218\u2013231","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"2621_CR32","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/01.mbc.0000167658.85143.49","volume":"16","author":"AB Federici","year":"2005","unstructured":"Federici AB (2005) Management of von Willebrand disease with factor VIII\/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 16(Suppl 1):S17\u201321","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2621_CR33","first-page":"533","volume":"4","author":"PA Mannucci PMPAK","year":"2013","unstructured":"Mannucci PMPAK PA, Schulman S, Di Paola J, Schneppenheim R, Cox Gill J (2013) Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor\/factor VIII concentrate in adults and children with von Willebrand\u2019s disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfusion 4:533\u2013540","journal-title":"Blood Transfusion"},{"issue":"8","key":"2621_CR34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/MBC.0b013e3280100d1e","volume":"17","author":"M Franchini","year":"2006","unstructured":"Franchini M, Veneri D, Lippi G (2006) The use of recombinant activated factor VII in congenital and acquired von Willebrand disease. Blood Coagul Fibrinolysis 17(8):615\u2013619","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"2621_CR35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1365-2516.2001.00500.x","volume":"7","author":"C Leissinger","year":"2001","unstructured":"Leissinger C, Becton D, Cornell C Jr, Cox GJ (2001) High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 7(3):258\u2013266","journal-title":"Haemophilia"},{"issue":"4","key":"2621_CR36","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Cervantes F et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778\u2013782","journal-title":"Blood"},{"issue":"5","key":"2621_CR37","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/clpt.1987.66","volume":"41","author":"SR Cox","year":"1987","unstructured":"Cox SR, VanderLugt JT, Gumbleton TJ, Smith RB (1987) Relationships between thromboxane production, platelet aggregability, and serum concentrations of ibuprofen or flurbiprofen. Clin Pharmacol Ther 41(5):510\u2013521","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2621_CR38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0609.1984.tb02390.x","volume":"33","author":"S Cronberg","year":"1984","unstructured":"Cronberg S, Wallmark E, Soderberg I (1984) Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 33(2):155\u2013159","journal-title":"Scand J Haematol"},{"issue":"7548","key":"2621_CR39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(68)90242-0","volume":"1","author":"JR O\u2019Brien","year":"1968","unstructured":"O\u2019Brien JR (1968) Effect of anti-inflammatory agents on platelets. Lancet 1(7548):894\u2013895","journal-title":"Lancet"},{"issue":"3","key":"2621_CR40","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/s-0037-1613027","volume":"87","author":"EJ Favaloro","year":"2002","unstructured":"Favaloro EJ, Bukuya M, Martinelli T et al (2002) A comparative multi-laboratory assessment of three factor VIII\/von Willebrand factor concentrates. Thromb Haemost 87(3):466\u2013476","journal-title":"Thromb Haemost"},{"issue":"1","key":"2621_CR41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2141.2011.08793.x","volume":"155","author":"P Harrison","year":"2011","unstructured":"Harrison P, Mackie I, Mumford A et al (2011) Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 155(1):30\u201344","journal-title":"Br J Haematol"},{"issue":"3\u20134","key":"2621_CR42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0049-3848(79)90145-2","volume":"15","author":"JS Fleming","year":"1979","unstructured":"Fleming JS, Buyniski JP (1979) A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb Res 15(3\u20134):373\u2013388","journal-title":"Thromb Res"},{"issue":"10","key":"2621_CR43","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J et al (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121(10):1720\u20131728","journal-title":"Blood"},{"issue":"5","key":"2621_CR44","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/leu.2011.306","volume":"26","author":"G Finazzi","year":"2012","unstructured":"Finazzi G (2012) How to manage essential thrombocythemia. Leukemia 26(5):875\u2013882","journal-title":"Leukemia"},{"issue":"10","key":"2621_CR45","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.20646","volume":"101","author":"M Steurer","year":"2004","unstructured":"Steurer M, Gastl G, Jedrzejczak WW et al (2004) Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 101(10):2239\u20132246","journal-title":"Cancer"},{"issue":"7","key":"2621_CR46","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood-2012-05-431288","volume":"121","author":"SF Moore","year":"2013","unstructured":"Moore SF, Hunter RW, Harper MT et al (2013) Dysfunction of the PI3 kinase\/Rap1\/integrin alpha(IIb)beta(3) pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia. Blood 121(7):1209\u20131219","journal-title":"Blood"},{"issue":"7","key":"2621_CR47","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood-2013-10-530832","volume":"124","author":"L Lamrani","year":"2014","unstructured":"Lamrani L, Lacout C, Ollivier V et al (2014) Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood 124(7):1136\u20131145","journal-title":"Blood"},{"issue":"1","key":"2621_CR48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00001721-200401000-00004","volume":"15","author":"V Afshar-Kharghan","year":"2004","unstructured":"Afshar-Kharghan V, Lopez JA, Gray LA et al (2004) Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 15(1):21\u201324","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"2621_CR49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T et al (2012) One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 87(1):25\u201333","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"2621_CR50","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, Nussenzveig RM, Popat U et al (2008) The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood 112(5):1628\u20131637","journal-title":"Blood"},{"issue":"1","key":"2621_CR51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L et al (2013) Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 6(1):81","journal-title":"J Hematol Oncol"},{"key":"2621_CR52","unstructured":"Bjorn ME, Holmstrom MO, Hasselbalch HC (2015) Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. Leuk Lymphoma. 2015:1\u20134"},{"issue":"12","key":"2621_CR53","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/imj.12921","volume":"45","author":"PJ Ho","year":"2015","unstructured":"Ho PJ, Marlton P, Tam C et al (2015) Practical management of myelofibrosis with ruxolitinib. Intern Med J 45(12):1221\u20131230","journal-title":"Intern Med J"},{"issue":"1","key":"2621_CR54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428194.2013.794269","volume":"55","author":"FP Santos","year":"2014","unstructured":"Santos FP, Tam CS, Kantarjian H et al (2014) Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma 55(1):121\u2013127","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2621_CR55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u2013435","journal-title":"N Engl J Med"},{"issue":"9","key":"2621_CR56","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798","journal-title":"N Engl J Med"},{"issue":"9","key":"2621_CR57","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807","journal-title":"N Engl J Med"},{"issue":"2","key":"2621_CR58","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/leu.2014.286","volume":"29","author":"RA Abdelrahman","year":"2015","unstructured":"Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Tefferi A (2015) Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. Leukemia 29(2):498\u2013500","journal-title":"Leukemia"},{"issue":"25","key":"2621_CR59","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ et al (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047\u20134053","journal-title":"Blood"},{"issue":"5","key":"2621_CR60","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/17474086.2013.827413","volume":"6","author":"C Harrison","year":"2013","unstructured":"Harrison C, Mesa R, Ross D et al (2013) Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol 6(5):511\u2013523","journal-title":"Expert Rev Hematol"},{"key":"2621_CR61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OTT.S53348","volume":"7","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Gotlib J, Gupta V et al (2013) Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther 7:13\u201321","journal-title":"Onco Targets Ther"},{"issue":"12","key":"2621_CR62","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","volume":"98","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98(12):1865\u20131871","journal-title":"Haematologica"},{"issue":"4","key":"2621_CR63","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","volume":"120","author":"S Verstovsek","year":"2014","unstructured":"Verstovsek S, Passamonti F, Rambaldi A et al (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120(4):513\u2013520","journal-title":"Cancer"},{"issue":"3","key":"2621_CR64","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","volume":"162","author":"RM Kaufman","year":"2015","unstructured":"Kaufman RM, Djulbegovic B, Gernsheimer T et al (2015) Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 162(3):205\u2013213","journal-title":"Ann Intern Med"},{"issue":"5","key":"2621_CR65","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/trf.12943","volume":"55","author":"A Kumar","year":"2015","unstructured":"Kumar A, Mhaskar R, Grossman BJ et al (2015) Platelet transfusion: a systematic review of the clinical evidence. Transfusion 55(5):1116\u20131127, quiz 1115","journal-title":"Transfusion"},{"issue":"6","key":"2621_CR66","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1160\/TH08-04-0205","volume":"99","author":"V Stefano De","year":"2008","unstructured":"De Stefano V, Rossi E, Za T, Chiusolo P, Leone G (2008) The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal. Thromb Haemost 99(6):1121","journal-title":"Thromb Haemost"},{"issue":"4","key":"2621_CR67","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1160\/TH14-03-0239","volume":"112","author":"CE Mahan","year":"2014","unstructured":"Mahan CE, Liu Y, Turpie AG et al (2014) External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost 112(4):692\u2013699","journal-title":"Thromb Haemost"},{"issue":"10","key":"2621_CR68","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224\u20132232","journal-title":"J Clin Oncol"},{"issue":"1","key":"2621_CR69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22\u201333","journal-title":"N Engl J Med"},{"issue":"3","key":"2621_CR70","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V Stefano De","year":"2008","unstructured":"De Stefano V, Za T, Rossi E et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93(3):372\u2013380","journal-title":"Haematologica"},{"issue":"6","key":"2621_CR71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.blre.2010.08.002","volume":"24","author":"E Papadakis","year":"2010","unstructured":"Papadakis E, Hoffman R, Brenner B (2010) Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev 24(6):227\u2013232","journal-title":"Blood Rev"},{"issue":"4","key":"2621_CR72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.thromres.2003.12.015","volume":"112","author":"T Bachleitner-Hofmann","year":"2003","unstructured":"Bachleitner-Hofmann T, Grumbeck E, Gisslinger H (2003) Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients. Thromb Res 112(4):229\u2013232","journal-title":"Thromb Res"},{"issue":"12","key":"2621_CR73","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00277-014-2224-8","volume":"93","author":"S Kreher","year":"2014","unstructured":"Kreher S, Ochsenreither S, Trappe RU et al (2014) Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the haemostasis working party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol 93(12):1953\u20131963","journal-title":"Ann Hematol"},{"issue":"6 Suppl","key":"2621_CR74","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1378\/chest.08-0674","volume":"133","author":"S Schulman","year":"2008","unstructured":"Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest P (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):257S\u2013298S","journal-title":"Chest"},{"issue":"8","key":"2621_CR75","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","volume":"117","author":"A Haouala","year":"2011","unstructured":"Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA (2011) Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117(8):e75\u201387","journal-title":"Blood"},{"issue":"9937","key":"2621_CR76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(14)61106-5","volume":"384","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Antman EM (2014) New oral anticoagulants in patients with atrial fibrillation\u2014authors\u2019 reply. Lancet 384(9937):25\u201326","journal-title":"Lancet"},{"issue":"9921","key":"2621_CR77","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955\u2013962","journal-title":"Lancet"},{"issue":"12","key":"2621_CR78","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","volume":"124","author":"N Es van","year":"2014","unstructured":"van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968\u20131975","journal-title":"Blood"},{"issue":"1","key":"2621_CR79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-9560-11-13","volume":"11","author":"MH Prins","year":"2013","unstructured":"Prins MH, Lensing AW (2013) Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J 11(1):13","journal-title":"Thromb J"},{"issue":"1","key":"2621_CR80","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","volume":"11","author":"MH Prins","year":"2013","unstructured":"Prins MH, Lensing AW, Bauersachs R et al (2013) Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 11(1):21","journal-title":"Thromb J"},{"issue":"6","key":"2621_CR81","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","volume":"134","author":"M Carrier","year":"2014","unstructured":"Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY (2014) Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 134(6):1214\u20131219","journal-title":"Thromb Res"},{"key":"2621_CR82","doi-asserted-by":"crossref","unstructured":"Hanken H, Grobe A, Heiland M, et al (2015) Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy. Clin Oral Investig","DOI":"10.1007\/s00784-015-1627-9"},{"key":"2621_CR83","doi-asserted-by":"crossref","unstructured":"Andras A, Sala Tenna A, Crawford F (2012) Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev; 10:CD002001","DOI":"10.1002\/14651858.CD002001.pub2"},{"issue":"6","key":"2621_CR84","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.thromres.2012.08.290","volume":"130","author":"S Laporte","year":"2012","unstructured":"Laporte S, Bertoletti L, Romera A, Mismetti P, de Llano LA P, Meyer G (2012) Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients. Thromb Res 130(6):853\u2013858","journal-title":"Thromb Res"},{"issue":"2","key":"2621_CR85","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146\u2013153","journal-title":"N Engl J Med"},{"issue":"1","key":"2621_CR86","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0002-9343(91)90513-W","volume":"90","author":"F Liote","year":"1991","unstructured":"Liote F, Yeni P, Teillet-Thiebaud F et al (1991) Ascites revealing peritoneal and hepatic extramedullary hematopoiesis with peliosis in agnogenic myeloid metaplasia: case report and review of the literature. Am J Med 90(1):111\u2013117","journal-title":"Am J Med"},{"issue":"4","key":"2621_CR87","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000204888","volume":"85","author":"A Lopez-Guillermo","year":"1991","unstructured":"Lopez-Guillermo A, Cervantes F, Bruguera M, Pereira A, Feliu E, Rozman C (1991) Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematol 85(4):184\u2013188","journal-title":"Acta Haematol"},{"issue":"16","key":"2621_CR88","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/BF01725198","volume":"67","author":"BR Anger","year":"1989","unstructured":"Anger BR, Seifried E, Scheppach J, Heimpel H (1989) Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 67(16):818\u2013825","journal-title":"Klin Wochenschr"},{"key":"2621_CR89","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","volume":"2012","author":"A Falanga","year":"2012","unstructured":"Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012:571\u2013581","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2621_CR90","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/CCO.0b013e3283592331","volume":"24","author":"A Falanga","year":"2012","unstructured":"Falanga A, Marchetti M, Russo L (2012) Venous thromboembolism in the hematologic malignancies. Curr Opin Oncol 24(6):702\u2013710","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"2621_CR91","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.thromres.2010.06.025","volume":"126","author":"J Duchemin","year":"2010","unstructured":"Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF (2010) Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 126(3):238\u2013242","journal-title":"Thromb Res"},{"issue":"9","key":"2621_CR92","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2011-02-339655","volume":"118","author":"M Panova-Noeva","year":"2011","unstructured":"Panova-Noeva M, Marchetti M, Buoro S et al (2011) JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 118(9):2599\u20132601","journal-title":"Blood"},{"issue":"3","key":"2621_CR93","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.25551","volume":"55","author":"WM Lee","year":"2012","unstructured":"Lee WM, Stravitz RT, Larson AM (2012) Introduction to the revised American Association for the Study of Liver Diseases position paper on acute liver failure 2011. Hepatology 55(3):965\u2013967","journal-title":"Hepatology"},{"issue":"11","key":"2621_CR94","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1097\/01.CCM.0000287592.94554.5F","volume":"35","author":"RT Stravitz","year":"2007","unstructured":"Stravitz RT, Kramer AH, Davern T et al (2007) Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 35(11):2498\u20132508","journal-title":"Crit Care Med"},{"issue":"20","key":"2621_CR95","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","volume":"33","author":"M Hultcrantz","year":"2015","unstructured":"Hultcrantz M, Wilkes SR, Kristinsson SY et al (2015) Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol 33(20):2288\u20132295","journal-title":"J Clin Oncol"},{"issue":"5","key":"2621_CR96","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","volume":"86","author":"FB Taylor Jr","year":"2001","unstructured":"Taylor FB Jr, Toh CH, Hoots WK et al (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86(5):1327\u20131330","journal-title":"Thromb Haemost"},{"issue":"5","key":"2621_CR97","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1365-2516.2003.00806.x","volume":"9","author":"T Biss","year":"2003","unstructured":"Biss T, Crossman L, Neilly I, Hanley J (2003) An acquired factor VIII inhibitor in association with a myeloproliferative\/myelodysplastic disorder presenting with severe subcutaneous haemorrhage. Haemophilia 9(5):638\u2013641","journal-title":"Haemophilia"},{"issue":"11","key":"2621_CR98","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3109\/10428194.2012.682309","volume":"53","author":"C Vener","year":"2012","unstructured":"Vener C, Artoni A, Boschetti C et al (2012) An acquired factor VIII inhibitor in a myeloproliferative neoplasm presenting with severe retroperitoneal hemorrhage. Leuk Lymphoma 53(11):2296\u20132298","journal-title":"Leuk Lymphoma"},{"key":"2621_CR99","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/JBM.S37631","volume":"3","author":"S Imashuku","year":"2012","unstructured":"Imashuku S, Kudo N, Kubo K, Saigo K, Okuno N, Tohyama K (2012) Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation. J Blood Med 3:157\u2013161","journal-title":"J Blood Med"},{"issue":"3","key":"2621_CR100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.21949","volume":"86","author":"M Kremyanskaya","year":"2011","unstructured":"Kremyanskaya M, Aledort L (2011) Acquired hemophilia: we now see it with myeloproliferative neoplasms. Am J Hematol 86(3):329\u2013330","journal-title":"Am J Hematol"},{"issue":"4","key":"2621_CR101","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1538-7836.2009.03303.x","volume":"7","author":"F Dentali","year":"2009","unstructured":"Dentali F, Squizzato A, Appio L, Brivio L, Ageno W (2009) JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease. J Thromb Haemost 7(4):722\u2013725","journal-title":"J Thromb Haemost"},{"issue":"22","key":"2621_CR102","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","volume":"113","author":"F Dentali","year":"2009","unstructured":"Dentali F, Squizzato A, Brivio L et al (2009) JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113(22):5617\u20135623","journal-title":"Blood"},{"issue":"12","key":"2621_CR103","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1365-2036.2010.04299.x","volume":"31","author":"DW Orr","year":"2010","unstructured":"Orr DW, Patel RK, Lea NC et al (2010) The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Aliment Pharmacol Ther 31(12):1330\u20131336","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2621_CR104","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clml.2014.04.004","volume":"15","author":"M Yan","year":"2015","unstructured":"Yan M, Geyer H, Mesa R et al (2015) Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. Clin Lymphoma Myeloma Leuk 15(1):e1\u20135","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"2621_CR105","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1002\/cncr.26741","volume":"118","author":"N Bejanyan","year":"2012","unstructured":"Bejanyan N, Tiu RV, Raza A et al (2012) A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) or primary myelofibrosis (PMF). Cancer 118(16):3968\u20133976","journal-title":"Cancer"},{"issue":"2","key":"2621_CR106","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000352088","volume":"6","author":"CS Link","year":"2013","unstructured":"Link CS, Platzbecker U, Kroschinsky F et al (2013) Association of oesophageal varices and splanchnic vein thromboses in patients with JAK2-positive myeloproliferative neoplasms: presentation of two cases and data from a retrospective analysis. Case Rep Oncol 6(2):311\u2013315","journal-title":"Case Rep Oncol"},{"issue":"2","key":"2621_CR107","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/gast.2001.21209","volume":"120","author":"B Condat","year":"2001","unstructured":"Condat B, Pessione F, Hillaire S et al (2001) Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 120(2):490\u2013497","journal-title":"Gastroenterology"},{"issue":"21","key":"2621_CR108","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1056\/NEJMc1203704","volume":"366","author":"S Koschmieder","year":"2012","unstructured":"Koschmieder S, Koppelle A, Seifert H (2012) Ruxolitinib for myelofibrosis. N Engl J Med 366(21):2031\u20132032, author reply 2032\u20132034","journal-title":"N Engl J Med"},{"issue":"2","key":"2621_CR109","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2516.2000.00370.x","volume":"6","author":"AB Federici","year":"2000","unstructured":"Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM (2000) Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia 6(2):71\u201377","journal-title":"Haemophilia"},{"issue":"5","key":"2621_CR110","first-page":"504","volume":"32","author":"G Carter","year":"2003","unstructured":"Carter G, Goss A (2003) Tranexamic acid mouthwash\u2014a prospective randomized study of a 2-day regimen vs 5-day regimen to prevent postoperative bleeding in anticoagulated patients requiring dental extractions. Int J Oral Maxillofac Surg 32(5):504\u2013507","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"12","key":"2621_CR111","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.joms.2003.01.001","volume":"61","author":"G Carter","year":"2003","unstructured":"Carter G, Goss A, Lloyd J, Tocchetti R (2003) Tranexamic acid mouthwash versus autologous fibrin glue in patients taking warfarin undergoing dental extractions: a randomized prospective clinical study. J Oral Maxillofac Surg 61(12):1432\u20131435","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2621-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2621-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2621-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T03:21:21Z","timestamp":1600226481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2621-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,26]]},"references-count":111,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["2621"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2621-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,26]]}}}